Key Takeaways
- • Dren Bio, a privately held, clinical-stage biotechnology company developing first-in-class antibody therapeutics for cancer, autoimmune, and other serious diseases, announced the closing of an oversubscribed $350 million private financing, according to a Business Wire release.
- • The round was co-led by Juvia Group and Lightspeed Venture Partners, with participation from an expanded syndicate of new investors including Mirae Asset Capital Life Science, General Catalyst, and Cormorant Asset Management.
- • The financing is intended to advance dibotatug toward commercialization and accelerate development of Dren Bio's broader pipeline.
Summary
Dren Bio, a San Carlos, California-based clinical-stage biotechnology company, has closed an oversubscribed $350 million private financing, according to a company announcement distributed via Business Wire. The company develops first-in-class antibody therapeutics targeting cancer, autoimmune disorders, and other serious diseases.
The round was co-led by Juvia Group and Lightspeed Venture Partners. It also drew participation from an expanded syndicate of new investors, including Mirae Asset Capital Life Science, General Catalyst, and Cormorant Asset Management. The oversubscription indicates demand exceeded the amount initially targeted, though the primary source does not specify the original offering size.
According to the announcement, proceeds will be used to advance dibotatug toward commercialization and to accelerate development of the company's broader pipeline. The primary source does not disclose further details on clinical timelines, valuation, or specific allocation of capital.
## END
The round was co-led by Juvia Group and Lightspeed Venture Partners. It also drew participation from an expanded syndicate of new investors, including Mirae Asset Capital Life Science, General Catalyst, and Cormorant Asset Management. The oversubscription indicates demand exceeded the amount initially targeted, though the primary source does not specify the original offering size.
According to the announcement, proceeds will be used to advance dibotatug toward commercialization and to accelerate development of the company's broader pipeline. The primary source does not disclose further details on clinical timelines, valuation, or specific allocation of capital.
## END
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.